Show simple item record

dc.contributor.authorMohebali, Donyaen_US
dc.contributor.authorMatos, Jasonen_US
dc.contributor.authorChang, James Ducksoonen_US
dc.date.accessioned2017-03-28T23:47:50Z
dc.date.issued2016en_US
dc.identifier.citationMohebali, Donya, Jason Matos, and James Ducksoon Chang. 2016. “Gemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicity.” Esc Heart Failure 4 (1): 71-74. doi:10.1002/ehf2.12113. http://dx.doi.org/10.1002/ehf2.12113.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:31731630
dc.description.abstractAbstract Gemcitabine is a commonly used antineoplastic agent used to treat a variety of cancers with rarely reported cardiac side effects. We describe a case of a 67‐year‐old woman with follicular lymphoma who experienced a rarely reported side effect of gemcitabine: cardiomyopathy. This case highlights a multiple hit mechanism of myocyte damage that may occur following the use of multiple cardio‐toxic agents despite their administration in doses not associated with cardiotoxicity.en
dc.language.isoen_USen
dc.publisherJohn Wiley and Sons Inc.en
dc.relation.isversionofdoi:10.1002/ehf2.12113en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292629/pdf/en
dash.licenseLAAen_US
dc.subjectCase Reporten
dc.subjectCardiomyopathyen
dc.subjectCardio‐oncologyen
dc.subjectChemotherapyen
dc.titleGemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicityen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalEsc Heart Failureen
dash.depositing.authorMohebali, Donyaen_US
dc.date.available2017-03-28T23:47:50Z
dc.identifier.doi10.1002/ehf2.12113*
dash.contributor.affiliatedMohebali, Donya
dash.contributor.affiliatedMatos, Jason


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record